<DOC>
	<DOCNO>NCT02227108</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy moxetumomab pasudotox pediatric participant relapse refractory B-cell acute lymphoblastic leukemia ( ALL ) B-cell lymphoblastic lymphoma .</brief_summary>
	<brief_title>Study Pediatrics With Relapsed Refractory Pediatric Acute Lymphoblastic Leukemia ( pALL ) Lymphoblastic Lymphoma</brief_title>
	<detailed_description>This global , multicenter , open-label , single-arm Phase 2 study evaluate efficacy safety moxetumomab pasudotox monotherapy pediatric participant relapse refractory B-cell ALL B-cell lymphoblastic lymphoma . Participants enrol site North America , Europe , Australia . This approximate 35 month study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Inclusion Criteria 1 . Between age great equal ( ≥ ) 6 month less ( &lt; ) 18 year age 2 . Must histologically proven Bcell acute lymphoblastic leukemia ( ALL ) Bcell lymphoblastic lymphoma marrow involvement 3 . All participant ( ALL participant lymphoblastic lymphoma ) must M2 M3 bone marrow classification 4 . Disease status : ) Participants must relapse refractory disease b ) In event relapse prior allogeneic hematopoietic stem cell transplant ( HSCT ) , participant must least 3 month posttransplant evidence active graftvshost disease , must immunosuppression least 4 week , c ) Must resolution acute toxic effect less equal ( ≤ ) Grade 2 prior chemotherapy entry , opinion investigator 5 . Participants follow central nervous system ( CNS ) 1 2 status eligible absence neurologic symptom 6 . Female participant childbearing potential postpubertal male participant must use approved method contraception study . Exclusion Criteria 1 . Concurrent enrollment another clinical study cancer treatment , unless subject followup period previous study . 2 . Isolated testicular CNS ALL 3 . Participants mixedlineage leukemia ( MLL ) gene rearrangement 4 . Inadequate Hepatic function 5 . Inadequate Renal function 6 . Radiologicallydetected CNS lymphoma 7 . Participants clear laboratory clinical evidence disseminate intravascular coagulation ( DIC ) 8 . Hyperleukocytosis rapidly progressive disease would compromise ability complete study therapy 9 . QT interval correct use Fridericia 's formula ( QTcF ) great equal Grade 2 , confirm 2 additional seperate electrocardiograph ( ECG 's ) within 28 day prior start study drug . The initial screening ECG need repeat confirmation QTcF interval &lt; 481 millisecond . 10 . Pregnant breastfeeding female 11 . Prior treatment CAT3888 ( BL22 ) , moxetumomab pasudotox , pseudomonasexotoxincontaining compound 12 . Prior treatment anticancer biologic therapy within 2 week prior start study drug , include limited therapeutic monoclonal antibody antibodydrug conjugate 13 . Systemic chemotherapy ≤ 2 week ( 6 week nitrosoureas ) radiation therapy ≤ 3 week prior start study drug 14 . Clinically significant ophthalmologic finding ( evidence retinal damage injury ) screen 15 . Presence second invasive malignancy 16 . Uncontrolled pulmonary infection , presence pulmonary edema 17 . Serum albumin &lt; 2 gram per deciliter ( g/dL ) . Albumin infusion correction hypoalbuminemia allow , administer within 7 day prior start study drug 18 . Radioimmunotherapy within 2 year prior study start study drug 19 . Participants prior history thrombotic microangiopathy hemolytic uremic syndrome ( HUS ) 20 . Tcell ALL Tcell lymphoblastic lymphoma 21 . Participants currently receive highdose estrogen therapy define &gt; 0.625 milligram per day ( mg/day ) estrogen compound within 2 week prior start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pediatric cancer , pediatric acute lymphoblastic leukemia , lymphoblastic lymphoma , B-cell leukemia , ALL , moxetumomab pasudotox , CD22</keyword>
</DOC>